Parkinson’s Disease Treatment Rank Ordered

In a 16-week observational study using Microdose Therapy(tm), The Helen Foundation ranks highest in all standard treatment efficacy records for Parkinson’s disease symptom improvement.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

(PRWEB) January 29, 2014

Thirty one (31) Parkinson’s disease patients achieved an average of 63% symptom relief in a 16-week, observational study using Microdose Therapy(tm). This breaks the previous efficacy record held by Sinemet(tm) of 7 to 20% symptom improvement. The percentage improvements for Sinemet(tm) vary with dosage. Microdose Therapy(tm) has one percentage improvement since it is patient self-administration of cortisol in which patients determine how much medicine is taken.    

Patient evaluation of improvement, i.e., patient global assessment, was selected to be the treatment comparison parameter in recognition that the objective of medicine is to improve patient health. Fortunately, patient global assessment is usually measured in clinical trials regardless of clinical trial, disease or disorder. If patient global assessment were not available, the Helen Foundation Committee selected another parameter measured that most approximates patient global assessment.

The parameters measured in a clinical trial are dependent upon the selection of those who designed the trial. The treatment effectiveness is ordinarily evaluated by a variety of parameters such as questionnaires, physical movement measurement, physician global assessment, and laboratory tests.

Microdose Therapy(tm) is a trade name for patient-self administration of cortisol developed by Professor Virgil Stenberg.

The Helen Foundation has undertaken the task of rank ordering the effectiveness of disease treatments to assist those in need. The Foundation does not evaluate side effects or cost of treatments.

For further information, corrections and additions, contact the Helen Foundation at 480-983-8376.


Contact